|
SHANGHAI, Feb. 9, 2026 /PRNewswire/ -- Chemistry serves as the foundational pillar of material innovation and transformation. It supports and shapes almost every aspect of modern industries. Recently, XtalPi Inc. (2228.HK), a global leader in AI- and robotics driven research and development (R&D) platform, announced the successful deployment of its automated formulation stability testing workstation at BASF, a world-renowned giant in the chemical industry. This collaboration enables BASF to build an end‑to‑end automated system that integrates sample management, analytical testing, and data management. Marking a significant milestone in XtalPi's advancements in chemical automation, this achievement further demonstrates the company's technological leadership and its ability to deliver highly specialized, scalable solutions to the most demanding industry leaders. With its state-of-the-art robotic laboratory platforms, exceptional customization capabilities, and cross-disciplinary adaptability, XtalPi is committed to driving innovation in pharmaceuticals, petrochemicals, new energy, and advanced materials, providing high-precision structured data that serves as the foundation for the digital and intelligent transformation of modern R&D.
As a global leader in the chemical industry, BASF operates across diverse sectors, such as chemicals, materials, industrial solutions, and nutrition & care and etc. The company is recognized for its technological leadership and commitment to driving the industry towards green transformation. At its Innovation Campus Shanghai, BASF annually evaluates the thousands of liquid raw materials and formulations for their long-term stability, which traditionally relied on manual workflows. These conventional methods require to test samples at various temperatures, visually observe for the phase separation, and manually record pH and viscosity data. This labor-intensive process is not only time-consuming but also prone to inconsistencies due to subjective evaluations and fragmented data recording.
Distinguished by its technical expertise, proven solutions, and strong industry reputation, XtalPi emerged as the partner of choice for BASF in a highly competitive selection process. To address BASF's challenges, XtalPi developed a cutting-edge automated workstation for formulation stability testing. This intelligent system seamlessly performs the entire testing process, from sample loading and barcode scanning to image-based analysis, pH measurement, and viscosity testing. By integrating these steps into a cohesive automated workflow, XtalPi has enabled BASF to achieve a new high level of efficiency, accuracy, and standardization, creating a streamlined system for managing samples, conducting tests, and processing data.
The project's success leveraged XtalPi's modular, standardized platform and its agile customization capabilities. This platform has already been successfully deployed across high-value domains such as drug discovery, chemical synthesis, and advanced material research, building a strong foundation of expertise. Its modular architecture ensures rapid deployment and operational stability while supporting customized adaptations to meet unique client and industry requirements. By deeply understanding BASF's specialized processes, XtalPi was able to seamlessly integrate bespoke functionalities, achieving a swift transition from a general-purpose solution to a fully customized workstation. This adaptability positions XtalPi to meet the complex and evolving demands of industrial-scale R&D, while also paving the way for its solutions to address broader markets in robotics-driven automation.
The near-flawless execution of this project for BASF, delivered in full alignment with stringent global standards, highlights XtalPi's advanced robotic automation capabilities and the maturity of its solutions. It further validates the XtalPi's ability to execute on a commercial scale, bolstering its reputation as a trusted leader in automated chemistry and robotic lab solutions. XtalPi's autonomous laboratories not only enable unparalleled standardization and throughput in experimental processes but also serve as a robust platform for generating high-fidelity with structured data. This continuous stream of high-quality data fuels the development and optimization of proprietary AI models, which are essential for advancing R&D capabilities across industries.
As artificial intelligence increasingly transforms the R&D landscape, the ability to automate experimentation and generate large-scale, high-precision data has become a cornerstone of future innovation. XtalPi has firmly established itself as a trailblazer in this space, carving out a distinct competitive edge with its unique integration of AI algorithms and large-scale robotic experimentation. Its intelligent laboratory solutions have consistently earned the trust and endorsement of leading global enterprises, driving technological evolution and operational excellence while delivering transformative results.
Today, XtalPi's automated laboratory solutions are deployed across a diverse range of industries and research institutions, including global pharmaceutical companies, Sinopec, Fudan University, Singapore Agency for Science, Technology, and Research (A*STAR) in Singapore, and the Hengqin Laboratory. Operating under a "standardized platform + agile customization" business model, XtalPi is rapidly expanding its reach beyond pharmaceutical R&D into trillion-dollar markets such as large-scale chemicals and renewable energy. By scaling its transformative solutions across these industries, XtalPi is unlocking new growth horizons and redefining the future of AI for Science.
Looking ahead, XtalPi is committed to deepening its strategic partnerships with global industry leaders. Through close collaboration with its partners, the company will continue to drive iterative advancements in combining AI with large-scale robotic experiments, leveraging its expertise to provide the next generation of core infrastructure for R&D. Together with its partners, XtalPi is accelerating the transformation of chemical research into a new era driven by AI and robotics.
About XtalPi
XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.
About BASF
At BASF, we create chemistry for a sustainable future. Our ambition: We want to be the preferred chemical company to enable our customers' green transformation. We combine economic success with environmental protection and social responsibility. Around 112,000 employees in the BASF Group contribute to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio comprises, as core businesses, the segments Chemicals, Materials, Industrial Solutions, and Nutrition & Care; our standalone businesses are bundled in the segments Surface Technologies and Agricultural Solutions. BASF generated sales of €65.3 billion in 2024. BASF shares are traded on the stock exchange in Frankfurt (BAS) and as American Depositary Receipts (BASFY) in the United States. Further information at www.basf.com.
SHANGHAI, Feb. 9, 2026 /PRNewswire/ -- Chemistry serves as the foundational pillar of material innovation and transformation. It supports and shapes almost every aspect of modern industries. Recently, XtalPi Inc. (2228.HK), a global leader in AI- and robotics driven research and development (R&D) platform, announced the successful deployment of its automated formulation stability testing workstation at BASF, a world-renowned giant in the chemical industry. This collaboration enables BASF to build an end‑to‑end automated system that integrates sample management, analytical testing, and data management. Marking a significant milestone in XtalPi's advancements in chemical automation, this achievement further demonstrates the company's technological leadership and its ability to deliver highly specialized, scalable solutions to the most demanding industry leaders. With its state-of-the-art robotic laboratory platforms, exceptional customization capabilities, and cross-disciplinary adaptability, XtalPi is committed to driving innovation in pharmaceuticals, petrochemicals, new energy, and advanced materials, providing high-precision structured data that serves as the foundation for the digital and intelligent transformation of modern R&D.
As a global leader in the chemical industry, BASF operates across diverse sectors, such as chemicals, materials, industrial solutions, and nutrition & care and etc. The company is recognized for its technological leadership and commitment to driving the industry towards green transformation. At its Innovation Campus Shanghai, BASF annually evaluates the thousands of liquid raw materials and formulations for their long-term stability, which traditionally relied on manual workflows. These conventional methods require to test samples at various temperatures, visually observe for the phase separation, and manually record pH and viscosity data. This labor-intensive process is not only time-consuming but also prone to inconsistencies due to subjective evaluations and fragmented data recording.
Distinguished by its technical expertise, proven solutions, and strong industry reputation, XtalPi emerged as the partner of choice for BASF in a highly competitive selection process. To address BASF's challenges, XtalPi developed a cutting-edge automated workstation for formulation stability testing. This intelligent system seamlessly performs the entire testing process, from sample loading and barcode scanning to image-based analysis, pH measurement, and viscosity testing. By integrating these steps into a cohesive automated workflow, XtalPi has enabled BASF to achieve a new high level of efficiency, accuracy, and standardization, creating a streamlined system for managing samples, conducting tests, and processing data.
The project's success leveraged XtalPi's modular, standardized platform and its agile customization capabilities. This platform has already been successfully deployed across high-value domains such as drug discovery, chemical synthesis, and advanced material research, building a strong foundation of expertise. Its modular architecture ensures rapid deployment and operational stability while supporting customized adaptations to meet unique client and industry requirements. By deeply understanding BASF's specialized processes, XtalPi was able to seamlessly integrate bespoke functionalities, achieving a swift transition from a general-purpose solution to a fully customized workstation. This adaptability positions XtalPi to meet the complex and evolving demands of industrial-scale R&D, while also paving the way for its solutions to address broader markets in robotics-driven automation.
The near-flawless execution of this project for BASF, delivered in full alignment with stringent global standards, highlights XtalPi's advanced robotic automation capabilities and the maturity of its solutions. It further validates the XtalPi's ability to execute on a commercial scale, bolstering its reputation as a trusted leader in automated chemistry and robotic lab solutions. XtalPi's autonomous laboratories not only enable unparalleled standardization and throughput in experimental processes but also serve as a robust platform for generating high-fidelity with structured data. This continuous stream of high-quality data fuels the development and optimization of proprietary AI models, which are essential for advancing R&D capabilities across industries.
As artificial intelligence increasingly transforms the R&D landscape, the ability to automate experimentation and generate large-scale, high-precision data has become a cornerstone of future innovation. XtalPi has firmly established itself as a trailblazer in this space, carving out a distinct competitive edge with its unique integration of AI algorithms and large-scale robotic experimentation. Its intelligent laboratory solutions have consistently earned the trust and endorsement of leading global enterprises, driving technological evolution and operational excellence while delivering transformative results.
Today, XtalPi's automated laboratory solutions are deployed across a diverse range of industries and research institutions, including global pharmaceutical companies, Sinopec, Fudan University, Singapore Agency for Science, Technology, and Research (A*STAR) in Singapore, and the Hengqin Laboratory. Operating under a "standardized platform + agile customization" business model, XtalPi is rapidly expanding its reach beyond pharmaceutical R&D into trillion-dollar markets such as large-scale chemicals and renewable energy. By scaling its transformative solutions across these industries, XtalPi is unlocking new growth horizons and redefining the future of AI for Science.
Looking ahead, XtalPi is committed to deepening its strategic partnerships with global industry leaders. Through close collaboration with its partners, the company will continue to drive iterative advancements in combining AI with large-scale robotic experiments, leveraging its expertise to provide the next generation of core infrastructure for R&D. Together with its partners, XtalPi is accelerating the transformation of chemical research into a new era driven by AI and robotics.
About XtalPi
XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.
About BASF
At BASF, we create chemistry for a sustainable future. Our ambition: We want to be the preferred chemical company to enable our customers' green transformation. We combine economic success with environmental protection and social responsibility. Around 112,000 employees in the BASF Group contribute to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio comprises, as core businesses, the segments Chemicals, Materials, Industrial Solutions, and Nutrition & Care; our standalone businesses are bundled in the segments Surface Technologies and Agricultural Solutions. BASF generated sales of €65.3 billion in 2024. BASF shares are traded on the stock exchange in Frankfurt (BAS) and as American Depositary Receipts (BASFY) in the United States. Further information at www.basf.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Leading Automation Capabilities of XtalPi Recognized by Global Chemical Giant - Successful Launch of Advanced Automated Workstation at BASF
|
MUMBAI, India, Feb. 9, 2026 /PRNewswire/ -- Made in India, written by Sundeep Khanna and Manish Sabharwal, traces three remarkable journeys: the rise of India's pharma industry, the birth and evolution of Lupin (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and the extraordinary life of its founder, Desh Bandhu Gupta. Together, the three journeys illuminate how a country once completely dependent on imported medicines became the world's pharmacy. The book shares how an individual's life, shaped early by adversity, growing up without privilege or patronage, unpredictably nurtured hunger and drive, to navigate an unforgiving state, blend national health priorities and global standards, to build a multibillion-dollar enterprise whose medicines reach patients in over 120 countries.
Made in India shows the distance travelled by a village boy from Rajasthan, who went on to become a teacher, professor and pharmaceutical employee, before founding a company worth $10 billion. It is the story of how an unlikely entrepreneur, given his role models, fought the system and left teaching and pharma jobs, going on to build a successful company, giving wings to a world-class industry and became a business icon for a nation.
Written with candor by TeamLease Services co-founder Manish Sabharwal and journalist Sundeep Khanna, the book confronts failures, financial crises, and the personal toll of leadership, alongside achievement and success, in the building of one of the world's biggest generics firms. This is a riveting portrait of entrepreneurship without mythmaking – of how institutions are built slowly, tested severely and rebuilt with resolve. Made in India weaves vivid anecdotes tracing Desh Bandhu Gupta's transformation from a humble professor to a pharma titan, finding his true calling in tending to the unmet needs of people. It issues a powerful call to future leaders, showcasing his journey of visionary entrepreneurship: rising from setbacks with raw grit and unshakeable conviction.
Made in India also spotlights Desh Bandhu Gupta's wife Manju Gupta's pivotal role amid the trials and triumphs of building Lupin. Together, the couple also built community service and rural support programs, even as Lupin and India became a reliable global supplier of pharmaceuticals.
India has today become the world's pharmacy: Nearly half of the 400 billion pills Americans consume every year are made in India, as are 60 per cent of the world's vaccines. Of the 700 US Food and Drug Administration-approved factories that sell medicines in the US, a third are located in India. The co-creators of Indian pharma – Dr. Yusuf Hamied (Cipla), Anji Reddy (Dr. Reddy's), Parvinder Singh (Ranbaxy), Dilip Shanghvi (Sun), Ramanbhai Patel (Zydus-Cadila), Habil Khorakiwala (Wockhardt) and DBG (Lupin) – matter more to India than their companies' revenues, exports or profits because they saw something no one else did. Together, they raised India's soft and hard power, demolished the myth that multinationals possess unfair advantages over Indian companies, and ended pessimism about India's ability to export goods, making pharma India's biggest manufacturing success. Together, they showed the world that a developing nation can dominate a complex industry when brilliant entrepreneurs meet smart policy. Together, they made India 'Pharmacy to the world'.
Made in India came alive during the launch as the authors, and the publisher shared their journeys, followed by a rich and engaging panel discussion on 'Past and Future of Indian Pharma' with pharma leaders Dilip Shanghvi, Sun Pharma, Dr. Yusuf Hamied, Cipla, G.V. Prasad, Dr. Reddy's, Vinita Gupta, Lupin, and Prof. M. M. Sharma, Ex-(UDCT) ICT. The panel discussed insights on leadership, nation-building, and the Indian pharma industry's crucial role in making healthcare affordable and accessible globally.
Praise for the book:
Dilip Sanghvi of Sun Pharma said, "DBG was a visionary whose heart beat for India and for Indian patients. His relentless focus on excellence defined his personality. He was a remarkable role model for all of us and one of the true architects who helped shape India's journey to becoming the pharmacy to the world".
Yusuf Hamied of Cipla said, "DBG built Lupin from extremely modest beginnings, guided by determination and a deep commitment to serving patients. DBG's life story is not only inspiring, but also a reminder of how one individuals purpose can make healthcare accessible and affordable across the world".
Made in India is a book for everyone thinking about India's place in the world, seeking role models of a world leading industry from India, entrepreneurs and business people looking for inspiration about building a valuable company, and finally, India's young and their parents, aiming to build ambition, exploration and determination.
About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 120 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. Lupin Human Welfare and Research Foundation has impacted more than 2.02 million beneficiaries across 5400 villages in 26 districts, spread across eight states in India.
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin
MUMBAI, India, Feb. 9, 2026 /PRNewswire/ -- Made in India, written by Sundeep Khanna and Manish Sabharwal, traces three remarkable journeys: the rise of India's pharma industry, the birth and evolution of Lupin (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and the extraordinary life of its founder, Desh Bandhu Gupta. Together, the three journeys illuminate how a country once completely dependent on imported medicines became the world's pharmacy. The book shares how an individual's life, shaped early by adversity, growing up without privilege or patronage, unpredictably nurtured hunger and drive, to navigate an unforgiving state, blend national health priorities and global standards, to build a multibillion-dollar enterprise whose medicines reach patients in over 120 countries.
Made in India shows the distance travelled by a village boy from Rajasthan, who went on to become a teacher, professor and pharmaceutical employee, before founding a company worth $10 billion. It is the story of how an unlikely entrepreneur, given his role models, fought the system and left teaching and pharma jobs, going on to build a successful company, giving wings to a world-class industry and became a business icon for a nation.
Written with candor by TeamLease Services co-founder Manish Sabharwal and journalist Sundeep Khanna, the book confronts failures, financial crises, and the personal toll of leadership, alongside achievement and success, in the building of one of the world's biggest generics firms. This is a riveting portrait of entrepreneurship without mythmaking – of how institutions are built slowly, tested severely and rebuilt with resolve. Made in India weaves vivid anecdotes tracing Desh Bandhu Gupta's transformation from a humble professor to a pharma titan, finding his true calling in tending to the unmet needs of people. It issues a powerful call to future leaders, showcasing his journey of visionary entrepreneurship: rising from setbacks with raw grit and unshakeable conviction.
Made in India also spotlights Desh Bandhu Gupta's wife Manju Gupta's pivotal role amid the trials and triumphs of building Lupin. Together, the couple also built community service and rural support programs, even as Lupin and India became a reliable global supplier of pharmaceuticals.
India has today become the world's pharmacy: Nearly half of the 400 billion pills Americans consume every year are made in India, as are 60 per cent of the world's vaccines. Of the 700 US Food and Drug Administration-approved factories that sell medicines in the US, a third are located in India. The co-creators of Indian pharma – Dr. Yusuf Hamied (Cipla), Anji Reddy (Dr. Reddy's), Parvinder Singh (Ranbaxy), Dilip Shanghvi (Sun), Ramanbhai Patel (Zydus-Cadila), Habil Khorakiwala (Wockhardt) and DBG (Lupin) – matter more to India than their companies' revenues, exports or profits because they saw something no one else did. Together, they raised India's soft and hard power, demolished the myth that multinationals possess unfair advantages over Indian companies, and ended pessimism about India's ability to export goods, making pharma India's biggest manufacturing success. Together, they showed the world that a developing nation can dominate a complex industry when brilliant entrepreneurs meet smart policy. Together, they made India 'Pharmacy to the world'.
Made in India came alive during the launch as the authors, and the publisher shared their journeys, followed by a rich and engaging panel discussion on 'Past and Future of Indian Pharma' with pharma leaders Dilip Shanghvi, Sun Pharma, Dr. Yusuf Hamied, Cipla, G.V. Prasad, Dr. Reddy's, Vinita Gupta, Lupin, and Prof. M. M. Sharma, Ex-(UDCT) ICT. The panel discussed insights on leadership, nation-building, and the Indian pharma industry's crucial role in making healthcare affordable and accessible globally.
Praise for the book:
Dilip Sanghvi of Sun Pharma said, "DBG was a visionary whose heart beat for India and for Indian patients. His relentless focus on excellence defined his personality. He was a remarkable role model for all of us and one of the true architects who helped shape India's journey to becoming the pharmacy to the world".
Yusuf Hamied of Cipla said, "DBG built Lupin from extremely modest beginnings, guided by determination and a deep commitment to serving patients. DBG's life story is not only inspiring, but also a reminder of how one individuals purpose can make healthcare accessible and affordable across the world".
Made in India is a book for everyone thinking about India's place in the world, seeking role models of a world leading industry from India, entrepreneurs and business people looking for inspiration about building a valuable company, and finally, India's young and their parents, aiming to build ambition, exploration and determination.
About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 120 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. Lupin Human Welfare and Research Foundation has impacted more than 2.02 million beneficiaries across 5400 villages in 26 districts, spread across eight states in India.
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
'Made in India - The story of Desh Bandhu Gupta, Lupin and Indian Pharma' Book Launched in Mumbai
'Made in India - The story of Desh Bandhu Gupta, Lupin and Indian Pharma' Book Launched in Mumbai
